Navigation Links
Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response
Date:11/30/2009

NEW YORK, Nov. 30 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response

http://www.reportlinker.com/p0165600/Inflammatory-Disorders-Therapies-That-Suppress-or-Balance-the-Immune-Response.html

The human immune system can go awry, either attacking an individual body or producing an exaggerated response to a foreign substance that is normally benign. In these situations, immunotherapies are needed to balance or suppress the unwarranted immune response. In this report:

  • Approximately 400 product candidates and development programs are identified.
  • Current and emerging therapies for selected autoimmune or inflammatory disorders and prevention of organ transplant rejection, directed against a wide range of putative targets, are summarized.
  • Specifically, more than 250 emerging autoimmune disease therapies, 80 asthma therapies in development, and 50+ therapy candidates for allergies are covered.
  • The strategic consequences of intense competition in a crowded product space are considered.

Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response reviews the problems of insufficient efficacy, side effects, and adverse events associated with the small-molecule and biological drugs available today to treat these disorders. These observations have led to an interest in identifying ways to balance the immune reaction, to suppress the part of the immune response that is causing the disease, while maintaining or enhancing other aspects of the immune system. This report identifies nearly 400 ongoing product candidates and development programs in these indication areas. The companies active in these areas range from multinational pharmaceutical companies with a number of active programs to small boutique start-ups working on a very defined topic.

CHAPTER 1: INTRODUCTION

1.1. The Immune System

1.2. Scope of the Report

CHAPTER 2: REVIEW OF MAJOR DISEASES/ CONDITIONS TARGETED BY NEW AND/OR EMERGING IMMUNOTHERAPIES AND VACCINES TO SUPPRESS OR BALANCE THE IMMUNE SYSTEM

2.1. Major Autoimmune Diseases

Rheumatoid Arthritis

Type 1 Diabetes Mellitus

Inflammatory Bowel Disease--Crohn's Disease and Ulcerative Colitis

Multiple Sclerosis

Psoriasis

Psoriatic Arthritis

Systemic Lupus Erythematosus

2.2. Asthma

2.3. Allergies

2.4. Immune Suppression to Prevent

Rejection of Organ Transplants

CHAPTER 3: CURRENT PHARMACOLOGICAL TREATMENT OPTIONS

3.1. Major Autoimmune Diseases

Rheumatoid Arthritis

Nonsteroidal Anti-inflammatory Drugs

(NSAIDs)

Disease-Modifying Antirheumatic

Drugs (DMARDs)

Corticosteroids

Biological Response Modifiers

Type 1 Diabetes Mellitus

Inflammatory Bowel Disease--Crohn's Disease and Ulcerative Colitis

Multiple Sclerosis

Interferon-beta

Copaxone (glatiramer acetate)

Novantrone (mitoxantrone)

Tysabri (natalizumab)

Psoriasis

Psoriatic Arthritis

Systemic Lupus Erythematosus

3.2. Asthma

3.3. Allergies

3.4. Immune Suppression to Prevent Rejection of Organ Transplants

CHAPTER 4: CURRENT AND EMERGING APPROACHES TO SUPPRESS OR BALANCE THE IMMUNE SYSTEM FOR PREVENTION AND TREATMENT OF DISEASE

CHAPTER 5: EMERGING THERAPIES IN DEVELOPMENT FOR TREATMENT OF MAJOR AUTOIMMUNE DISEASES

5.1. Introduction

5.2. Abbott Laboratories

5.3. Biogen Idec

5.4. AstraZeneca

5.5. Bristol-Myers Squibb

5.6. Centocor Ortho Biotech

5.7. Centocor Ortho Biotech and Schering-Plough

5.8. Diamyd Medical

5.9. Eli Lilly and BioMS Medical

5.10. Eli Lilly and MacroGenics

5.11. Genzyme and Bayer

5.12. GlaxoSmithKline and Genmab

5.13. GlaxoSmithKline and Human Genome Sciences

5.14. GlaxoSmithKline and Tolerx

5.15. GlaxoSmithKline (Selected Additional Product Candidates and Research)

5.16. Isotechnika

5.17. Merck Serono and ZymoGenetics

5.18. Merck Serono

5.19. Novartis

Multiple Sclerosis

Rheumatoid Arthritis

Psoriasis

5.20. Pfizer

5.21. Roche and Chugai Pharmaceutical

5.22. Roche and Genentech (A Wholly-Owned Member of the Roche Group)

5.23. Sanofi-Aventis

5.24. Takeda Pharmaceutical and Millennium Pharmaceuticals

5.25. Teva Pharmaceutical Industries and Active Biotech

5.26. UCB

CHAPTER 6: EMERGING THERAPIES FOR TREATMENT OF ASTHMA

6.1. Pipeline Overview

6.2. Abbott Laboratories and SkyePharma (Also Mundipharma and Kyorin)

6.3. Aerovance

6.4. Amgen

6.5. AstraZeneca

6.6. Ception Therapeutics

6.7. Genentech

6.8. GlaxoSmithKline

6.9. Icagen

6.10. MediciNova

6.11. Pfizer

6.12. Schering-Plough and Novartis

6.13. Topigen Pharmaceuticals

6.14. Wyeth

CHAPTER 7: SELECTED EXAMPLES OF EMERGING THERAPIES FOR TREATMENT OF ALLERGIES

7.1. Introduction

7.2. ALK-Abello and Schering-Plough

7.3. Allergy Therapeutics

7.4. Ception Therapeutics

7.5. Cytos Biotechnology

7.6. Greer Laboratories

7.7. Stallergenes

CHAPTER 8: IMMUNOTHERAPIES IN DEVELOPMENT FOR PREVENTING REJECTION OF ORGAN TRANSPLANTS

8.1. Introduction

8.2. APT Pharmaceuticals

8.3. Astellas Pharma

8.4. Bristol-Myers Squibb

8.5. Isotechnika

8.6. Novartis

8.7. Pfizer

CHAPTER 9: BUSINESS CONSIDERATIONS --THERAPIES THAT SUPPRESS OR BALANCE THE IMMUNE SYSTEM

9.1. Current Market and Market Potential

9.2. Competition

9.3. Strong Interest on the Part of Major Pharmaceutical Companies

9.4. Agreements and Mergers/Acquisitions

9.5. Other Major Challenges and Hurdles Being Faced by Companies

Competition

Potential Need for Personalized Medicine in at Least Certain Situations

Targeted Patient Populations

CHAPTER 10: THOUGHT LEADER INTERVIEWS

10.1. David W. Pritchard, President and Chief Executive Officer, KaloBios

10.2. Randall C. Schatzman, PhD, President and Chief Executive Officer, Alder Biopharmaceuticals

10.3. Louis Vaickus, MD, Chief Medical Officer, Tolerx

10.4. Eric H. Zanelli, PhD, Vice President, Research, Peptimmune

REFERENCES

COMPANY INDEX WITH WEB ADDRESSES

To order this report:

Therapy Industry: Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response

More Market Research Report


Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015
2. Reportlinker Adds Mammography Equipment - A Global Market Perspective
3. Reportlinker Adds Pain Management - Global Trends
4. Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis
5. Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015
6. Reportlinker Adds India Dental Devices Investment Opportunities, Analysis and Forecasts to 2015
7. Reportlinker Adds U.S. Market for PACS and EMR
8. Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective
9. Reportlinker Adds Holter Monitoring Systems - A Global Market Review
10. Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review
11. Reportlinker Adds Anesthesia Disposables - A World Market Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... DUBLIN , Feb. 8, 2016 /PRNewswire/ ... announced the addition of the "Label-Free ... Global Forecasts to 2020" report to ... has announced the addition of the ... - Global Forecasts to 2020" report ...
(Date:2/8/2016)... Pa. , Feb. 8, 2016  Unilife Corporation ("Unilife" ... and supplier of injectable drug delivery systems, today announced that ... six months ended December 31, 2015 after market close on ... scheduled a conference call to discuss these financial results.    ... Unilife Corporation --> About Unilife Corporation ...
(Date:2/8/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), ... the U.S. Food and Drug Administration (FDA) has ... for SB-318, a single treatment strategy intended to ... (MPS I). The SB-318 IND application is now ... 1/2 clinical study (SB-318-1502) designed to assess the ...
Breaking Medicine Technology:
(Date:2/8/2016)... CA (PRWEB) , ... February 08, 2016 , ... Delta ... $792,000 to help combat pancreatic cancer. , Gary D. Radine, who recently retired as ... was the American Cancer Society’s 2015 CEO of the Year , helped lead ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Discover the ... visit over 1,400 booths and 700 companies. Attendees also get to see the ... Colorado Garden & Home Show , at the Colorado Convention Center - 700 ...
(Date:2/8/2016)... ... 08, 2016 , ... Guruji Mahendra Kumar Trivedi is offering 3 days of ... of his birthday on February 10th. During this time, people can achieve better ... over 250,000 people from over 40 different countries as an “ordinary man with an ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced ... with the tools and information to lower the costs, and increase the impact ... of providing employee healthcare benefits by as much as 22%:, + Price ...
(Date:2/6/2016)... ... 06, 2016 , ... Shark Finds and Kevin Harrington, along with ... DRTV campaign with Belly Bands. , Having a dog is great—except when it wets ... and find nothing works, get Belly Bands, the easiest way to stop dogs ...
Breaking Medicine News(10 mins):